ELIMINATION OF ANTIPYRINE AND ITS METABOLITES IN INTERFERON-TREATED HEPATITIS-C

被引：4

作者：

SIECK, JO

ELYAZIGI, A

ALI, H

DOSSING, M

SAOUR, J

RAINES, DA

ERNST, P

机构：

[1] BISPEBJERG HOSP,DEPT MED P,DK-2400 COPENHAGEN,DENMARK

[2] KING FAISAL SPECIALIST HOSP & RES CTR,DEPT MED,RIYADH 11211,SAUDI ARABIA

[3] KING FAISAL SPECIALIST HOSP & RES CTR,DEPT BIOL & MED RES,RIYADH 11211,SAUDI ARABIA

[4] KING FAISAL SPECIALIST HOSP & RES CTR,DEPT ONCOL,RIYADH 11211,SAUDI ARABIA

来源：

HUMAN & EXPERIMENTAL TOXICOLOGY | 1994年 / 13卷 / 09期

关键词：

D O I：

10.1177/096032719401300902

中图分类号：

R99 [毒物学（毒理学）];

学科分类号：

100405 ;

摘要：

1 To study the effect of interferon on hepatic drug metabolism in chronic hepatitis C, we examined nine patients before and at the end of 6 months of interferon treatment. 2 Routine liver function was determined together with the salivary clearance of antipyrine and the 48 h urinary excretion of the main metabolites of antipyrine: 4-hydroxyantipyrine 3-hydroxymethylantipyrine and norantipyrine before and after 6 months of interferon treatment. 3 Liver pathology, routine liver function, and antipyrine metabolism remained unchanged after patients were treated for 6 months with interferon for a histologically advanced but clinically compensated chronic hepatitis C. ,

引用

收藏

页码：598 / 601

页数：4

相关论文

共 19 条

[1] TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].

DAVIS, GL ;

BALART, LA ;

SCHIFF, ER ;

LINDSAY, K ;

BODENHEIMER, HC ;

PERRILLO, RP ;

CAREY, W ;

JACOBSON, IM ;

PAYNE, J ;

DIENSTAG, JL ;

VANTHIEL, DH ;

TAMBURRO, C ;

LEFKOWITCH, J ;

ALBRECHT, J ;

MESCHIEVITZ, C ;

ORTEGO, TJ ;

GIBAS, A .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506

[2] RECOMBINANT INTERFERON-ALFA THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DIBISCEGLIE, AM ;

MARTIN, P ;

KASSIANIDES, C ;

LISKERMELMAN, M ;

MURRAY, L ;

WAGGONER, J ;

GOODMAN, Z ;

BANKS, SM ;

HOOFNAGLE, JH .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1506-1510

[3] OPTIMAL SAMPLING TIMES FOR MINIMUM VARIANCE OF CLEARANCE DETERMINATION [J].

DOSSING, M ;

VOLUND, A ;

POULSEN, HE .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (02) :231-235

[4] A SIMPLE METHOD FOR DETERMINATION OF ANTIPYRINE CLEARANCE [J].

DOSSING, M ;

POULSEN, HE ;

ANDREASEN, PB ;

TYGSTRUP, N .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (03) :392-396

[5] EFFECTS OF SUBCHRONIC TREATMENT WITH NATURAL HUMAN INTERFERONS ON ANTIPYRINE CLEARANCE AND LIVER-FUNCTION IN PATIENTS WITH CHRONIC HEPATITIS [J].

ECHIZEN, H ;

OHTA, Y ;

SHIRATAKI, H ;

TSUKAMOTO, K ;

UMEDA, N ;

ODA, T ;

ISHIZAKI, T .

JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (06) :562-567

[6]

ELIN RJ, 1975, CLIN PHARMACOL THER, V17, P447

[7]

ELYAZIGI A, 1991, PHARMACEUT RES, V2, P269

[8] RANDOMIZED CONTROLLED TRIAL OF INTERFERON-ALPHA (LYMPHOBLASTOID INTERFERON) IN CHRONIC NON-A-HEPATITIS NON-B-HEPATITIS [J].

JACYNA, MR ;

BROOKS, MG ;

LOKE, RHT ;

MAIN, J ;

MURRAYLYON, IM ;

THOMAS, HC .

BRITISH MEDICAL JOURNAL, 1989, 298 (6666) :80-82

[9] FORMULATION AND APPLICATION OF A NUMERICAL SCORING SYSTEM FOR ASSESSING HISTOLOGICAL ACTIVITY IN ASYMPTOMATIC CHRONIC ACTIVE HEPATITIS [J].

KNODELL, RG ;

ISHAK, KG ;

BLACK, WC ;

CHEN, TS ;

CRAIG, R ;

KAPLOWITZ, N ;

KIERNAN, TW ;

WOLLMAN, J .

HEPATOLOGY, 1981, 1 (05) :431-435

[10] INTRODUCTION TO SAMPLE-SIZE DETERMINATION AND POWER ANALYSIS FOR CLINICAL-TRIALS [J].

LACHIN, JM .

CONTROLLED CLINICAL TRIALS, 1981, 2 (02) :93-113